Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109837 | 1.00 | LMNA (0.46) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL17998104 | 1.00 | LMNA (0.46) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL27160377 | 1.00 | LMNA (0.46) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL8130163 | 0.98 | KDM4E (0.47) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL381079 | 0.94 | KDM4E (0.44) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL849912 | 0.87 | KDM4E (0.38) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL21997565 | 0.85 | KDM4E (0.35) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL13327112 | 0.84 | CA14 (0.36) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL22164325 | 0.84 | CA14 (0.34) | L3MBTL1HDAC1HDAC2HDAC6CA14 | |
| SCHEMBL21070068 | 0.82 | PDK2 (0.34) | LMNAKDM4EUSP2ALDH1A1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011083387-A1 | HYDROCHLORIDE SALT OF BIPHENYL-2-YL-CARBAMIC ACID 1-{9-[(3-FLUORO-4-HYDROXY-BENZOYL)-METHYL-AMINO]-NONYL}-PIPERIDIN-4-YL ESTER | PFIZER LIMITED (GB) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011083387-A1 | HYDROCHLORIDE SALT OF BIPHENYL-2-YL-CARBAMIC ACID 1-{9-[(3-FLUORO-4-HYDROXY-BENZOYL)-METHYL-AMINO]-NONYL}-PIPERIDIN-4-YL ESTER | PFIZER LIMITED (GB) | 2011-07-14 | — | — | WO | disclosed |
| CN-102099334-A | Novel compounds active as muscarinic receptor antagonists | PFIZER LTD | 2011-06-15 | — | — | CN | disclosed |
| EP-2328868-A1 | NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010007552-A1 | NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007552-A1 | NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | LMNA 3477/4885KDM4E 3484/4885USP2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.